Logo image
Back
TMET-56. Targeting transsulfuration via suppression of thyroid hormone signaling: a modified phase 1/2 and pharmacodynamic trial of methimazole in patients with progressive WHO grade 4 gliomas
Abstract   Open access   Peer reviewed

TMET-56. Targeting transsulfuration via suppression of thyroid hormone signaling: a modified phase 1/2 and pharmacodynamic trial of methimazole in patients with progressive WHO grade 4 gliomas

David Peereboom, Andras Ponti, Kailin Yang, Lilyana Angelov, Gene Barnett, Christine Cordova, Andrew Dhawan, Lea El Hage, Matthew Grabowsky, Rachel Hufsey, …
Neuro-oncology (Charlottesville, Va.), Vol.27(Supplement_5), pp.v441-v441
11/11/2025
DOI: 10.1093/neuonc/noaf201.1747
PMCID: PMC12601656
url
https://doi.org/10.1093/neuonc/noaf201.1747View
Published (Version of record) Open Access

Abstract

BACKGROUND Gaseous hydrogen sulfide (H2S), a by-product of cysteine metabolism, inhibits cancer cell behavior and growth in glioblastoma (GBM) models. H2S production capacity (HPC) is decreased in human GBM specimens compared to non-tumor controls. Thus, boosting HPC is a novel strategy for GBM treatment. Suppression of thyroid hormone signaling increases production of H2S. Hypothesis: methimazole-induced hypothyroidism will increase tumor HPC to enhance chemotherapy efficacy in GBM. GOAL Proof of concept that methimazole, by reducing thyroid hormone signaling, can increase HPC in patients with recurrent/progressive GBM (rGBM). PRIMARY ENDPOINTS 10% increase in HPC and a 1.5-fold increase in peripheral blood sulfhydration signaling. METHODS This window of opportunity trial evaluates safety, HPC in plasma and tumor, and efficacy of methimazole + chemotherapy in patients with rGBM. rGBM patients planned for a resection begin methimazole 15 mg/d 5-7 days pre-op with investigator’s choice chemotherapy added 10-28 days post-op. Patients receive combination until progression. Pre- and post-op plasma and resected tumor tissue are assayed for HPC and proteins relevant to H2S production. Key eligibility: rGBM for whom a clinically-indicated resection is planned; normal thyroid function with no history of thyroid dysfunction. Patients may have received unlimited prior regimens including bevacizumab. RESULTS To date 15 patients (8 male), median age 56 years, enrolled. The trial was amended to increase methimazole to 25 mg/d; 3 patients have received this dose. Median TSH rose from 1.3 mU/ml to 20.5 at cycle 6. Free T3 and T4 did not fall significantly. Median plasma HPC rose 3-fold while tumor HPC did not rise significantly. No treatment-related grade 3-5 toxicities. Efficacy: PFS6 – 15% and OS12 – 21%. CONCLUSIONS Induction of subclinical hypothyroidism is feasible and safe in rGBM with significant increases in plasma but not tumor HPC. Further tumor correlative data for the dose-escalated methimazole will be presented.

Details

Metrics

3 Record Views
Logo image